Cancer Therapy News and Research

RSS

U of A researchers try to combat heart disease in cancer patients

Researchers in the Faculty of Medicine & Dentistry are trying to reverse a devastating trend: cancer survivors developing cardiovascular disease, one of the top two killers in Canada.

4 Jun 2011

Scientists find way to protect kidney from cancer drug toxicity

Scientists may have a way to make the powerful cancer drug cisplatin less toxic to the kidneys and more effective against some cancers.

4 Jun 2011

Five years after cancer treatment, many survivors still suffer symptoms

When people finish treatment for cancer, they want to bounce back to their former vital selves as quickly as possible. But a new Northwestern Medicine study -- one of the largest survivor studies ever conducted - shows many survivors still suffer moderate to severe problems with pain, fatigue, sleep, memory and concentration three to five years after treatment has ended.

4 Jun 2011

Response Genetics' clinical approaches to improve cancer care to be presented at ASCO 2011

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today five presentations to be held during the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL from June 3 to June 7, 2011.

4 Jun 2011

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

Brain cancer therapy may be more effective if the expression of an iron-storing protein is decreased to enhance the action of therapeutic drugs on brain cancer cells, according to Penn State College of Medicine researchers.

4 Jun 2011

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.

4 Jun 2011

Cancer vaccine shows improved response rate in patients

A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to research led by scientists from The University of Texas MD Anderson Cancer Center and Indiana University Health Goshen Center for Cancer Care.

3 Jun 2011

Delayed treatment could prove effective in certain medical conditions

In today's fast-paced world, waiting — whether it's at the doctor's office, in line at the grocery store or for an Internet connection — is rarely considered a good thing.

3 Jun 2011

Lung-sparing surgery, photodynamic therapy improve survival of mesothelioma patients

Pleural mesothelioma patients who undergo lung-sparing surgery in combination with photodynamic therapy (PDT) show superior overall survival than patient treated using the conventional therapy of extrapleural pneumonectomy (EPP) with PDT, indicates new research from the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania.

3 Jun 2011

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease.

3 Jun 2011

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

SGO's Clinical Document outlines expert recommendations for gynecologic cancer surveillance

Although gynecologic cancers account for only 10 percent of all new cancer cases in women, these cancers account for 20 percent of all female cancer survivors. Because long-term survival is now more common, it is increasingly important to detect recurrence.

1 Jun 2011

Lymphoma vaccine extends disease-free survival by 14 months

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.

1 Jun 2011

Cancer drug helps prevent hypertensive heart disease

A promising cancer treatment drug can restore function of a heart en route to failure from high blood pressure, researchers at UT Southwestern Medical Center have found.

31 May 2011

Transgenomic secures exclusive license from Montefiore for cancer predictive markers

Transgenomic, Inc. announced today that it has acquired an exclusive worldwide license to Montefiore Medical Center's patent application, "Method of Determining the Sensitivity of Cancer Cells to EGFR Inhibitors including cetuximab, panitumumab and erlotinib".

27 May 2011

Lactate shuttle also exists in human tumors

Researchers at the Kimmel Cancer Center at Jefferson have shed new light on the longstanding conundrum about what makes a tumor grow-and how to make it stop. Interestingly, cancer cells accelerate the aging of nearby connective tissue cells to cause inflammation, which ultimately provides "fuel" for the tumor to grow and even metastasize.

27 May 2011

Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive breast cancer

Tigris Pharmaceuticals, Inc., today announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 with or without Faslodex in estrogen receptor (ER)-positive breast cancer patients.

27 May 2011

Positive interim results from new bladder cancer therapy trial

Clinical trials for a new bladder cancer therapy show promising interim results. Lead researcher Alvaro Morales says that the breakthrough using the drug Urocidin follows thirty years of his research in this important area.

25 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

Stony Brook University CFB establishes Biotechnology Commercialization Fund

The Center for Biotechnology (CFB) at Stony Brook University has established the Biotechnology Commercialization Fund to accelerate the development of promising biomedical technologies emerging from Stony Brook University.

21 May 2011

Cancer Therapy News and Research

U of A researchers try to combat heart disease in cancer patients

Scientists find way to protect kidney from cancer drug toxicity

Five years after cancer treatment, many survivors still suffer symptoms

Response Genetics' clinical approaches to improve cancer care to be presented at ASCO 2011

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

Cancer vaccine shows improved response rate in patients

Delayed treatment could prove effective in certain medical conditions

Lung-sparing surgery, photodynamic therapy improve survival of mesothelioma patients

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

SGO's Clinical Document outlines expert recommendations for gynecologic cancer surveillance

Lymphoma vaccine extends disease-free survival by 14 months

Cancer drug helps prevent hypertensive heart disease

Transgenomic secures exclusive license from Montefiore for cancer predictive markers

Lactate shuttle also exists in human tumors

Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive breast cancer

Positive interim results from new bladder cancer therapy trial

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Stony Brook University CFB establishes Biotechnology Commercialization Fund

Your guide to microplate readers for cancer research eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News